Several investigations have proposed that GSI therapy decreases the amount of active Notch1 protein and reduces Notch target genes in T-ALL cell lines with Notch1-activated alterations, resulting in G1 cell cycle arrest and cell size reduction [76]. Here, NOTCH1 is linked to acute lymphoblastic leukemia.